Midodrine for the Early Liberation of Vasopressor Support in the ICU (LIBERATE Multi-Site)

• Status: Recruiting
• Trial end date: 2024-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Vasopressors are medications that are given intravenously to increase the blood pressure of patients with illnesses that cause dangerous blood pressure drops. When a doctor prescribes a vasopressor, they ask that the dose be adjusted to achieve a specific blood pressure. This kind of medical support with intravenous (IV) vasopressors are usual treatments in intensive care unit (ICU) settings. Oral vasopressors, such as midodrine, have been historically used to maintain blood pressure in non-critically ill patients. In this study, the investigators will be using midodrine to reduce the need for IV vasopressors as blood pressure improves during the stay in the ICU.

The LIBERATE multi-site study will continue the work of the pilot study to evaluate the role of midodrine for patients with low blood pressure in the ICU.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Alberta
• Collaborators: Alberta Health Services; Institute of Health Economics, Canada; University Hospital Foundation
• Treatments: Midodrine

Criteria

Inclusion Criteria:

• Age > 18 years

• Ongoing vasopressor support

• Decreasing vasopressor dose(s)

Exclusion Criteria:

• Greater than 24 hours from peak vasopressor dose

• Contraindication to enteral medications

• Previously received midodrine in last 7 days

• Expected death or anticipated withdrawal of life-sustaining therapies in next 24 hours

• Pregnancy

• Known allergy to midodrine